Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 57-63

  de Haan, Willeke ^a,b   van der Hoogt, Caroline C ^a,b   Westerterp, Marit ^a,b   Hoekstra, Menno ^d   Dallinga Thie, Geesje M ^e   Princen, Hans M G ^a   Romijn, Johannes A ^b   Jukema, J Wouter ^a,c   Havekes, Louis M ^a,b,c   Rensen, Patrick C N ^a,b  

^a TNO   (Netherlands)

^b Endocrinology   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

CETP; High density lipoprotein; HMGCoA reductase; Statin; Transgenic mice

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E3; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRROLES; RNA, MESSENGER;

EID: 39449098454     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.08.001     Document Type: Article

References (30)

1. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
2. Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 (2004) 1427-1436
3. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
4. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
5. Jukema J.W., Liem A.H., Dunselman P.H., et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (rosuvastatin and atorvastatin in different dosages and reverse cholesterol transport) study. Curr Med Res Opin 21 (2005) 1865-1874
6. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
7. Le Goff W., Guerin M., and Chapman M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 101 (2004) 17-38
8. Guerin M., Lassel T.S., Le Goff W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
9. van Venrooij F.V., Stolk R.P., Banga J.D., et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diab Care 26 (2003) 1216-1223
10. van Vlijmen B.J., van den Maagdenberg A.M., Gijbels M.J., et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93 (1994) 1403-1410
11. Delsing D.J., Jukema J.W., van de Wiel M.A., et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 42 (2003) 63-70
12. Westerterp M., van der Hoogt C.C., de Haan W., et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
13. Dullaart R.P., Riemens S.C., Scheek L.M., and Van Tol A. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. Eur J Clin Invest 29 (1999) 663-671
14. Post S.M., Groenendijk M., Solaas K., Rensen P.C., and Princen H.M. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 24 (2004) 768-774
15. Van Eck M., Twisk J., Hoekstra M., et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 278 (2003) 23699-23705
16. Delsing D.J., Post S.M., Groenendijk M., et al. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J Cardiovasc Pharmacol 45 (2005) 53-60
17. Verschuren L., Kleemann R., Offerman E.H., et al. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 25 (2005) 161-167
18. Quarfordt S.H., Oswald B., Landis B., et al. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J Lipid Res 36 (1995) 1227-1235
19. Sparrow C.P., Burton C.A., Hernandez M., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 (2001) 115-121
20. Bisgaier C.L., Essenburg A.D., Auerbach B.J., et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res 38 (1997) 2502-2515
21. Gautier T., Tietge U.J., Boverhof R., et al. Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. J Lipid Res 48 (2007) 30-40
22. Plump A.S., Erickson S.K., Weng W., et al. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest 97 (1996) 2660-2671
23. Timmins J.M., Lee J.Y., Boudyguina E., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115 (2005) 1333-1342
24. Foger B., Santamarina-Fojo S., Shamburek R.D., et al. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 272 (1997) 27393-27400
25. Out R., Hoekstra M., Spijkers J.A., et al. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res 45 (2004) 2088-2095
26. Gauthier A., Lau P., Zha X., Milne R., and McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 25 (2005) 2177-2184
27. Collet X., Tall A.R., Serajuddin H., et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 40 (1999) 1185-1193
28. Luo Y., and Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105 (2000) 513-520
29. Libby P., and Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 91 (2003) 4B-8B
30. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504